WASHINGTON--(BUSINESS WIRE)--The Global Alzheimer's Platform Foundation® (GAP) and the Scottish Funding Council’s Brain Health ARC have announced swift progress in the next steps of the Bio-Hermes ...

Bio-Hermes-002 is the unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as ...

Washington D.C., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Washington D.C., Feb. 28, 2024- The Global Alzheimer’s Platform Foundation ®, (GAP) is releasing the first results from the Bio-Hermes-001 Study.

Washington D.C., Oct. 28, 2024 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These ...

WASHINGTON, July 31, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) and the Alzheimer’s Disease Data Initiative (AD Data Initiative) announced today that data generated ...

WASHINGTON--(BUSINESS WIRE)--The Global Alzheimer's Platform Foundation ® (GAP) – which is focused on global game-changing dementia research – has chosen Scotland to host the Bio-Hermes Biomarker Data ...

NEW YORK CITY, NY, UNITED STATES, December 10, 2024 /EINPresswire.com/ -- ViewMind Inc., a leader in eye movement technology, announces its participation in the Bio ...

IXICO joins collaborative study of new biomarkers designed to improve diagnosis of Alzheimer's disease and dementias WASHINGTON, July 22, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform ...

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets digital solutions to assess brain health, is pleased to have been selected to provide voice and touchscreen cognitive ...

Washington D.C., Jan. 23, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 ...